SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
17.86
-0.76 (-4.08%)
Apr 28, 2026, 5:29 PM CET
-10.52%
Market Cap 1.00B
Revenue (ttm) n/a
Net Income (ttm) -110.83M
Shares Out 56.00M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE 17.51
Dividend n/a
Ex-Dividend Date n/a
Volume 192,544
Average Volume 168,224
Open 18.64
Previous Close 18.62
Day's Range 17.64 - 18.64
52-Week Range 13.40 - 25.30
Beta 0.99
RSI 60.51
Earnings Date Apr 15, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.